ECSP22019193A - Proteínas de fijación multiespecíficas para tratamiento contra el cáncer antecedentes de la invención - Google Patents

Proteínas de fijación multiespecíficas para tratamiento contra el cáncer antecedentes de la invención

Info

Publication number
ECSP22019193A
ECSP22019193A ECSENADI202219193A ECDI202219193A ECSP22019193A EC SP22019193 A ECSP22019193 A EC SP22019193A EC SENADI202219193 A ECSENADI202219193 A EC SENADI202219193A EC DI202219193 A ECDI202219193 A EC DI202219193A EC SP22019193 A ECSP22019193 A EC SP22019193A
Authority
EC
Ecuador
Prior art keywords
proteins
binding proteins
against cancer
treatment against
multispecific binding
Prior art date
Application number
ECSENADI202219193A
Other languages
English (en)
Inventor
Michael Dziegelewski
Paul Adam
Susanne Hipp
Priyanka Gupta
Vladimir H Voynov
Philip Nicholas Gorman
Rajkumar Ganesan
Pankaj Gupta
Marcio Lasaro
Justin M Scheer
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ECSP22019193A publication Critical patent/ECSP22019193A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a proteínas de fijación a B7H6/CD3 novedosas. La invención también se refiere a ácidos nucleicos que codifican tales proteínas; a métodos para preparar tales proteínas; a células huésped que expresan o son capaces de expresar tales proteínas; a composiciones que comprenden tales proteínas; y a usos de tales proteínas o tales composiciones, en particular, con fines terapéuticos en el campo de las enfermedades cancerosas.
ECSENADI202219193A 2019-10-02 2022-03-14 Proteínas de fijación multiespecíficas para tratamiento contra el cáncer antecedentes de la invención ECSP22019193A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19201200 2019-10-02
PCT/EP2020/077586 WO2021064137A2 (en) 2019-10-02 2020-10-01 Multi-specific binding proteins for cancer treatment

Publications (1)

Publication Number Publication Date
ECSP22019193A true ECSP22019193A (es) 2022-04-29

Family

ID=68136317

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202219193A ECSP22019193A (es) 2019-10-02 2022-03-14 Proteínas de fijación multiespecíficas para tratamiento contra el cáncer antecedentes de la invención

Country Status (19)

Country Link
US (2) US11732045B2 (es)
EP (1) EP4038100A2 (es)
JP (2) JP7387885B2 (es)
KR (1) KR20220075383A (es)
CN (1) CN114641496A (es)
AR (1) AR120138A1 (es)
AU (1) AU2020358893A1 (es)
BR (1) BR112022004047A2 (es)
CA (1) CA3153372A1 (es)
CL (1) CL2022000664A1 (es)
CO (1) CO2022003552A2 (es)
CR (1) CR20220136A (es)
EC (1) ECSP22019193A (es)
IL (1) IL291817A (es)
JO (1) JOP20220079A1 (es)
MX (1) MX2022004042A (es)
PE (1) PE20221412A1 (es)
TW (1) TW202128756A (es)
WO (1) WO2021064137A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230162013A (ko) 2021-03-26 2023-11-28 이나뜨 파르마 에스.에이. Nk 세포 관여를 위해 사이토카인에 융합된 nkp46-결합 부위, 암 항원 결합 부위를 포함하는 다중특이적 단백질
US12065427B2 (en) 2021-04-29 2024-08-20 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating STING
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
EP4352098A1 (en) 2021-06-09 2024-04-17 Innate Pharma Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
CN114395047B (zh) * 2021-12-07 2023-11-07 合肥天港免疫药物有限公司 双特异性抗体及其应用
CN114395043B (zh) * 2021-12-07 2023-07-11 合肥天港免疫药物有限公司 Ncr3lg1抗体及其应用
CN114395045B (zh) * 2021-12-07 2023-06-09 合肥天港免疫药物有限公司 B7h6抗体及其应用
WO2024089006A1 (en) 2022-10-26 2024-05-02 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting
WO2024088991A1 (en) 2022-10-26 2024-05-02 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting
WO2024089008A1 (en) 2022-10-26 2024-05-02 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US168A (en) 1837-04-17 Improvement in fire-arms
US5731A (en) 1848-08-22 Elisha k
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5664905A (en) 1992-08-10 1997-09-09 Alcan Aluminium Uk Limited Fence
EP1621554B2 (en) 1992-08-21 2012-08-29 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US6193969B1 (en) 1993-06-03 2001-02-27 Protherics Inc. Antibody fragments in therapy
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
RU2420537C2 (ru) 2001-01-17 2011-06-10 Трабьон Фармасьютикалз Инк. Слитые белки связывающий домен-иммуноглобулин
US20050214857A1 (en) 2001-12-11 2005-09-29 Algonomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
NL1019562C2 (nl) 2001-12-13 2003-06-17 Heineken Tech Services Klepsamenstel voor gebruik bij drankafgifte.
US8764654B2 (en) 2008-03-19 2014-07-01 Zin Technologies, Inc. Data acquisition for modular biometric monitoring system
KR101472250B1 (ko) 2005-10-12 2014-12-11 모르포시스 아게 인간 ｃｄ38에 특이적인 완전 인간 ｈｕｃａｌ ｇｏｌｄ-유도 치료 항체들의 생성 및 프로파일링
AU2008308509B2 (en) 2007-10-04 2014-10-23 Zymogenetics, Inc. B7 family member zB7H6 and related compositions and methods
EP2235064B1 (en) 2008-01-07 2015-11-25 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
FI20090280A (fi) 2009-07-17 2011-01-18 Kone Corp Hissijärjestely ja menetelmä hissikorin liikuttamiseksi hissikuilussa
BR112012017051A2 (pt) 2009-12-23 2017-12-05 Esbatech Alcon Biomed Res Unit método para diminuir a imunogenicidade
SG10201509588TA (en) * 2011-05-21 2015-12-30 Macrogenics Inc CD3-Binding Molecules Capable Of Binding To Human And Non-Human CD3
MX350074B (es) 2011-06-23 2017-08-25 Ablynx Nv Tecnicas para predecir, detectar, y reducir la interferencia de proteinas no especificas en ensayos que implican dominios variables individuales de inmunoglobulina.
MX2014001883A (es) 2011-08-17 2014-05-27 Glaxo Group Ltd Proteinas y peptidos modificados.
DK2766392T3 (da) * 2011-10-10 2019-10-07 Xencor Inc Fremgangsmåde til oprensning af antistoffer
US9790278B2 (en) * 2012-05-07 2017-10-17 The Trustees Of Dartmouth College Anti-B7-H6 antibody, fusion proteins, and methods of using the same
CN104640561A (zh) * 2012-07-23 2015-05-20 酵活有限公司 包含轻链和重链的选择性配对的免疫球蛋白构建体
AU2017238172B2 (en) * 2016-03-21 2024-06-27 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
US11034767B2 (en) 2016-04-15 2021-06-15 Trustees Of Dartmouth College High affinity B7-H6 antibodies and antibody fragments
RS61510B1 (sr) 2016-05-18 2021-03-31 Boehringer Ingelheim Int Anti pd-1 i anti-lag3 antitela za lečenje kancera
AU2019280900A1 (en) * 2018-06-09 2020-11-19 Boehringer Ingelheim International Gmbh DLL3-CD3 bispecific antibodies

Also Published As

Publication number Publication date
MX2022004042A (es) 2022-05-02
US20230340130A1 (en) 2023-10-26
IL291817A (en) 2022-06-01
AU2020358893A1 (en) 2022-03-31
BR112022004047A2 (pt) 2022-05-24
EP4038100A2 (en) 2022-08-10
CA3153372A1 (en) 2021-04-08
CL2022000664A1 (es) 2023-01-06
CO2022003552A2 (es) 2022-04-19
KR20220075383A (ko) 2022-06-08
US20210107983A1 (en) 2021-04-15
JP2024020414A (ja) 2024-02-14
JP7387885B2 (ja) 2023-11-28
WO2021064137A2 (en) 2021-04-08
JP2022551081A (ja) 2022-12-07
PE20221412A1 (es) 2022-09-20
WO2021064137A3 (en) 2021-05-14
AR120138A1 (es) 2022-02-02
TW202128756A (zh) 2021-08-01
JOP20220079A1 (ar) 2023-01-30
US11732045B2 (en) 2023-08-22
CN114641496A (zh) 2022-06-17
CR20220136A (es) 2022-05-27

Similar Documents

Publication Publication Date Title
ECSP22019193A (es) Proteínas de fijación multiespecíficas para tratamiento contra el cáncer antecedentes de la invención
CL2021002094A1 (es) Moléculas de anticuerpo para el tratamiento del cáncer. (divisional solicitud 201803153)
JOP20200313A1 (ar) أجسام مضادة dll3-cd3 ثنائية الخاصية
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
SA520411173B1 (ar) Pd-l1 عوامل ربط ترتبط بـ واستخدامها cd137
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
MX2021003554A (es) Proteinas de union a dll3 y metodos de uso.
CR20190276A (es) Nuevos receptores de células t y terapia inmunológica que los utiliza
CR20190278A (es) Nuevos receptores de células t y terapia inmunológica que los utiliza
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
BR112017010110A2 (pt) anticorpos contra cd73 e usos do mesmo
EP4378962A3 (en) Anti-cancer fusion polypeptide
DOP2015000110A (es) Anticuerpos anti-ceacam5 y usos de estos
BR112022019020A2 (pt) Proteínas de fusão de il12 mascaradas e métodos de uso das mesmas
CO7010783A2 (es) Proteína naglu humana recombinante y usos de la misma
MX2017011794A (es) Composiciones y metodos para diagnosticos y tratamiento del cancer.
EA201692255A1 (ru) Улучшенные формы селективного ингибитора pi3k-дельта для применения в фармацевтических препаратах
AU2017329645A8 (en) Novel antibodies against Factor XI and uses thereof
UY37630A (es) Combinación farmacéutica, kit, célula huésped que la produce y su uso en métodos para el tratamiento del cáncer
CO2019013150A2 (es) Variantes de proteína morfogénica ósea humana 7 (bmp7)
AR115506A1 (es) Proteínas de fijación multiespecífica para el tratamiento del cáncer
MX2024003615A (es) Anticuerpos que se unen al cumulo de diferenciacion 30 (cd30) y al cumulo de diferenciacion 3 (cd3).
WO2022236276A3 (en) Anti-tigit antibodies, anti-cd96 antibodies, and methods of use thereof